Microbot Medical Enhances its Scientific Advisory Board (SAB) with its Newest Member Dr. Vincent Vidal
Retrieved on:
Thursday, September 15, 2022
Faculty of Medicine, Diponegoro University, ESR, Federal, COVID-19, FDA, Vision Guided Robotic Systems, Coronavirus Scientific Advisory Board (Turkey), Faculty, Growth, Intellectual property, Private Securities Litigation Reform Act, Internet, Maintenance, Forward-looking statement, U.S. Securities and Exchange Commission, Patient, Interventional radiology, CIRSE, Physician, CEO, Aix-Marseille University, Technology, CE, Goal, SAB, Nasdaq, Doctor of Philosophy, Health, NASDAQ, SCS, Research, SIR, Security (finance), GLOBE, SEC, School, Failure, Medicine, Medical device, Medicine
HINGHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a network of global leaders in the endovascular interventional space for the LIBERTY Robotic System, today announced that Vincent Vidal, M.D., PhD, has joined its Scientific Advisory Board (SAB).
Key Points:
- HINGHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a network of global leaders in the endovascular interventional space for the LIBERTY Robotic System, today announced that Vincent Vidal, M.D., PhD, has joined its Scientific Advisory Board (SAB).
- and PhD from the School of Medicine of Aix-Marseille University, and he is an active member of SIR, CIRSE, ESR, and APSCVIR.
- Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body.
- Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.